These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 27528467

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia.
    Ptasnuka M, Ozolins A, Narbuts Z, Truskovs A, Sperga M, Plaudis H.
    World J Surg; 2020 Feb; 44(2):585-593. PubMed ID: 31605174
    [Abstract] [Full Text] [Related]

  • 3. A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.
    Wu Z, Shang G, Zhang K, Wang W, Fan M, Lin R.
    Int J Surg; 2024 Apr 01; 110(4):2178-2186. PubMed ID: 38241384
    [Abstract] [Full Text] [Related]

  • 4. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M, Zhao P, Shi X, Zhao A, Zhang L, Zhou L.
    BMC Endocr Disord; 2017 Jul 13; 17(1):39. PubMed ID: 28705205
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C, Wang W, Zhang Y, Feng X, Sun J, Zeng Y, Chen Y, Li Y, Chen M, Zhou Z, Chen J.
    Chin J Cancer; 2017 Jun 21; 36(1):51. PubMed ID: 28637502
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
    Baeg K, Harris C, Naparst MS, Ahn E, Thapi S, Martin J, Rustgi S, Mhango G, Wisnivesky J, Kim MK.
    BMC Cancer; 2021 Feb 09; 21(1):146. PubMed ID: 33563241
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R.
    Oncologist; 2018 Apr 09; 23(4):422-432. PubMed ID: 29330208
    [Abstract] [Full Text] [Related]

  • 11. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Tumors.
    Fitzgerald TL, Mosquera C, Lea CS, McMullen M.
    Am Surg; 2017 Jul 01; 83(7):799-803. PubMed ID: 28738955
    [Abstract] [Full Text] [Related]

  • 12. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H, Perren A, Scoazec JY, Tang LH, Federspiel B, Klimstra DS, Vestermark LW, Ali AS, Zlobec I, Myklebust TÅ, Hjortland GO, Langer SW, Gronbaek H, Knigge U, Tiensuu Janson E, Sorbye H.
    Neuroendocrinology; 2021 Jul 01; 111(9):883-894. PubMed ID: 33002892
    [Abstract] [Full Text] [Related]

  • 13. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
    Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P.
    Oncologist; 2016 Oct 01; 21(10):1191-1199. PubMed ID: 27401895
    [Abstract] [Full Text] [Related]

  • 14. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute.
    Shin Y, Ha SY, Hyeon J, Lee B, Lee J, Jang KT, Kim KM, Park YS, Park CK.
    Cancer Res Treat; 2015 Oct 01; 47(4):738-46. PubMed ID: 25687852
    [Abstract] [Full Text] [Related]

  • 15. [Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy].
    Holzer K.
    Chirurg; 2014 Aug 01; 85(8):731-44. PubMed ID: 25103842
    [Abstract] [Full Text] [Related]

  • 16. An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm.
    Liu H, Xie R, Zhao Z, Xu D, Yang K, Ding M, Tan D, Liao W, Han X, Zhang J, Shen D, Yuan J, Xu Z, Fei J.
    Medicine (Baltimore); 2020 Aug 14; 99(33):e21682. PubMed ID: 32872039
    [Abstract] [Full Text] [Related]

  • 17. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.
    Zhang X, Ma L, Bao H, Zhang J, Wang Z, Gong P.
    BMC Endocr Disord; 2014 Jul 08; 14():54. PubMed ID: 25001493
    [Abstract] [Full Text] [Related]

  • 18. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS, Chen M, Kim JH, Kim WH, Ahn S, Maeng K, Allegra CJ, Kaye FJ, Hochwald SN, Zajac-Kaye M.
    Int J Cancer; 2014 Jul 01; 135(1):128-37. PubMed ID: 24347111
    [Abstract] [Full Text] [Related]

  • 19. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years.
    Desai GS, Pande P, Chhabra V, Shah RC, Jagannath P.
    Indian J Gastroenterol; 2019 Oct 01; 38(5):399-410. PubMed ID: 31802438
    [Abstract] [Full Text] [Related]

  • 20. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A.
    J Nucl Med; 2014 Feb 01; 55(2):183-90. PubMed ID: 24434296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.